Literature DB >> 10815914

High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.

A Eggert1, N Ikegaki, J Kwiatkowski, H Zhao, G M Brodeur, B P Himelstein.   

Abstract

Angiogenesis is essential for tumor growth and metastasis and depends on the production of angiogenic factors by tumor cells. Neuroblastoma (NB) is a common pediatric tumor of neural crest origin, which is biologically and clinically heterogeneous. Increased tumor vascular index correlates with poor outcome of NB. To determine which angiogenic factors contribute to NB angiogenesis and thereby support tumor progression, we examined the expression of eight angiogenic factors [vascular endothelial growth factor (VEGF), VEGF-B, VEGF-C, basic fibroblast growth factor, angiopoietin (Ang)-1, Ang-2, transforming growth factor alpha, and platelet-derived growth factor (PDGF)] by semiquantitative RT-PCR in 37 NB primary tumors and in 22 NB cell lines. We also analyzed the relationship between angiogenic factor expression and clinicopathological factors as well as patient survival. All eight angiogenic factors examined were expressed at various levels in NB cell lines and tumors, suggesting their involvement in NB angiogenesis. The expression levels of most angiogenic factors were correlated with each other, suggesting their synergy in regulating the angiogenic process. Significantly higher expression levels of VEGF, VEGF-B, VEGF-C, basic fibroblast growth factor, Ang-2, transforming growth factor alpha, and PDGF-A (P < 0.0001-0.026) were found in advanced-stage tumors (stages 3 and 4) compared with low-stage tumors (stages 1, 2, and 4S). Expression of PDGF-A was significantly associated with patient survival (P = 0.04). The redundancy in angiogenic factor expression suggests that inhibition of VEGF bioactivity alone might not be a sufficient approach for antiangiogenic therapy of human NB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815914

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  84 in total

1.  Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.

Authors:  Saritha Sandra D'Souza; Karine Scherzinger-Laude; Marc Simon; Bharathi P Salimath; Jochen Rössler
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-10       Impact factor: 4.553

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Tumor cell dynamics and metastasis in advanced neuroblastoma.

Authors:  Tatsuo Kuroda; Toshiro Honna; Nobuyuki Morikawa; Yoshihiro Kitano; Yasushi Fuchimoto; Kan Terawaki; Masaaki Kumagai; Yukiko Tsunematsu; Hidekazu Masaki; Kentaro Matsuoka; Morihiro Saeki
Journal:  Pediatr Surg Int       Date:  2005-11       Impact factor: 1.827

4.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

Review 5.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

6.  Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.

Authors:  Nibal Zaghloul; Sonia L Hernandez; Jae-O Bae; Jianzhong Huang; Jason C Fisher; Alice Lee; Angela Kadenhe-Chiweshe; Jessica J Kandel; Darrell J Yamashiro
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

7.  Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  Invest New Drugs       Date:  2009-09-24       Impact factor: 3.850

8.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

9.  Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.

Authors:  W T Arscott; A E LaBauve; V May; U V Wesley
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

10.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.